866-997-4948(US-Canada Toll Free)

Colorectal Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Cancer

No. of Pages : 872 Pages


Global Markets Directs, \'Colorectal Cancer Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colorectal Cancer. 

Colorectal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Colorectal Cancer.
  • A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Colorectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 8
Colorectal Cancer Overview 9
Therapeutics Development 10
Colorectal Cancer Therapeutics under Development by Companies 12
Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 25
Mid Clinical Stage Products 26
Early Clinical Stage Products 27
Discovery and Pre-Clinical Stage Products 28
Colorectal Cancer Therapeutics - Products under Development by Companies 29
Colorectal Cancer Therapeutics - Products under Investigation by Universities/Institutes 44
Companies Involved in Colorectal Cancer Therapeutics Development 46
Colorectal Cancer - Therapeutics Assessment 155
Drug Profiles 163
Colorectal Cancer Therapeutics - Drug Profile Updates 662
Colorectal Cancer Therapeutics - Discontinued Products 816
Colorectal Cancer Therapeutics - Dormant Products 819
Colorectal Cancer - Product Development Milestones 834

Appendix 843

List of Table


Number of Products Under Development for Colorectal Cancer, H1 2013 38
Products under Development for Colorectal Cancer - Comparative Analysis, H1 2013 39
Number of Products under Development by Companies, H1 2013 41
Number of Products under Investigation by Universities/Institutes, H1 2013 51
Comparative Analysis by Late Stage Development, H1 2013 53
Comparative Analysis by Mid Clinical Stage Development, H1 2013 54
Comparative Analysis by Early Clinical Stage Development, H1 2013 55
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 56
Products under Development by Companies, H1 2013 57
Products under Investigation by Universities/Institutes, H1 2013 72
Bristol-Myers Squibb Company, H1 2013 74
Boehringer Ingelheim GmbH, H1 2013 75
F. Hoffmann-La Roche Ltd., H1 2013 76
Kyowa Hakko Kirin Co., Ltd., H1 2013 77
Amgen Inc., H1 2013 78
Sanofi-Aventis, H1 2013 79
AstraZeneca PLC, H1 2013 80
Eli Lilly and Company, H1 2013 81
Viralytics Ltd., H1 2013 82
GlaxoSmithKline plc, H1 2013 83
Tekmira Pharmaceuticals Corp., H1 2013 84
Genentech, Inc., H1 2013 85
Gilead Sciences, Inc., H1 2013 87
Daiichi Sankyo Company, Ltd, H1 2013 88
Merck & Co., Inc., H1 2013 89
AbGenomics International, Inc., H1 2013 90
Oxford BioMedica plc, H1 2013 91
Otsuka Pharmaceutical Co., Ltd., H1 2013 92
Takeda Pharmaceutical Company Limited, H1 2013 93
Light Sciences Oncology, Inc., H1 2013 94
Celltrion, Inc., H1 2013 95
Novartis AG, H1 2013 96
Aphios Corporation, H1 2013 97
Astellas Pharma Inc., H1 2013 98
Chong Kun Dang Pharmaceutical, H1 2013 99
CK Life Sciences Int\'l., (Holdings) Inc., H1 2013 100
Eisai Co., Ltd., H1 2013 101
Nippon Kayaku Co., Ltd., H1 2013 102
Pfizer Inc., H1 2013 103
SuperGen, Inc., H1 2013 104
Taiho Pharmaceutical Co., Ltd., H1 2013 105
Teva Pharmaceutical Industries Limited, H1 2013 106
Cell Therapeutics, Inc., H1 2013 107
Enzon Pharmaceuticals, Inc., H1 2013 108
Santaris Pharma A/S, H1 2013 109
Aduro BioTech, H1 2013 110
Bayer AG, H1 2013 111
Merck KGaA, H1 2013 112
4SC AG, H1 2013 113
Alchemia Limited, H1 2013 114
EntreMed, Inc., H1 2013 115
Enzo Biochem, Inc., H1 2013 116
AEterna Zentaris Inc., H1 2013 117
IMMUNOMEDICS, INC, H1 2013 118
Idera Pharmaceuticals, Inc., H1 2013 119
Bionomics Limited, H1 2013 120
Neuren Pharmaceuticals Limited, H1 2013 121
Oncolytics Biotech Inc., H1 2013 122
Oncothyreon Inc, H1 2013 123
Compugen Ltd., H1 2013 124
Critical Outcome Technologies Inc., H1 2013 125
ARQULE, INC, H1 2013 126
Telik, Inc., H1 2013 127
Zenotech Laboratories Limited, H1 2013 128
Regeneron Pharmaceuticals, Inc., H1 2013 129
Dendreon Corporation, H1 2013 130
Antisoma plc, H1 2013 131
Green Cross Corporation, H1 2013 132
Synta Pharmaceuticals Corp., H1 2013 134
Panacea Biotec Limited, H1 2013 135
CrystalGenomics, Inc., H1 2013 136
BioAlliance Pharma SA, H1 2013 137
ThromboGenics NV, H1 2013 138
Morphotek, Inc., H1 2013 139
Cancer Research Technology Limited, H1 2013 140
Oryzon, H1 2013 141
Antisense Pharma GmbH, H1 2013 142
Chipscreen Biosciences Ltd, H1 2013 143
Supratek Pharma Inc., H1 2013 144
Fusion Antibodies Ltd, H1 2013 145
Actinium Pharmaceuticals, Inc., H1 2013 146
Multimmune GmbH, H1 2013 147
Nerviano Medical Sciences S.r.l., H1 2013 148
immatics biotechnologies GmbH, H1 2013 150
Celator Pharmaceuticals, Inc., H1 2013 151
MacroGenics, Inc., H1 2013 152
ACT Biotech, Inc., H1 2013 153
OncoMed Pharmaceuticals, Inc., H1 2013 154
Boston Biomedical, Inc., H1 2013 155
DanDrit Biotech A/S, H1 2013 156
Merrimack Pharmaceuticals, Inc., H1 2013 157
CritiTech, Inc., H1 2013 158
Jennerex Biotherapeutics, Inc., H1 2013 159
MolMed S.p.A., H1 2013 160
Globeimmune, Inc., H1 2013 161
Etubics Corporation, H1 2013 162
CG Therapeutics, Inc., H1 2013 163
Quintessence Biosciences, Inc., H1 2013 164
CureTech Ltd., H1 2013 165
Lipopharma, H1 2013 166
Biothera, H1 2013 167
Nereus Pharmaceuticals, Inc., H1 2013 168
AVEO Pharmaceuticals, Inc., H1 2013 169
3-V Biosciences, Inc., H1 2013 170
Cancer Therapeutics CRC Pty Ltd, H1 2013 171
Interprotein Corporation, H1 2013 172
RECEPTA Biopharma S.A., H1 2013 173
ISU ABXIS Co.,Ltd., H1 2013 174
Cytavis Biopharma GmbH, H1 2013 175
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2013 176
Medical Enzymes AG, H1 2013 177
Therapure Biopharma Inc., H1 2013 178
Regulon Inc., H1 2013 180
Gradalis Inc., H1 2013 181
Oncozyme Pharma Inc., H1 2013 182
Assessment by Monotherapy Products, H1 2013 183
Assessment by Combination Products, H1 2013 184
Assessment by Stage and Route of Administration, H1 2013 187
Assessment by Stage and Molecule Type, H1 2013 190
Colorectal Cancer Therapeutics - Drug Profile Updates 690
Colorectal Cancer Therapeutics - Discontinued Products 844
Colorectal Cancer Therapeutics - Dormant Products 847

List of Chart


Number of Products under Development for Colorectal Cancer, H1 2013 38
Products under Development for Colorectal Cancer - Comparative Analysis, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Investigation by Universities/Institutes, H1 2013 50
Late Stage Products, H1 2013 53
Mid Clinical Stage Products, H1 2013 54
Early Clinical Stage Products, H1 2013 55
Discovery and Pre-Clinical Stage Products, H1 2013 56
Assessment by Monotherapy Products, H1 2013 183
Assessment by Combination Products, H1 2013 184
Assessment by Route of Administration, H1 2013 185
Assessment by Stage and Route of Administration, H1 2013 186
Assessment by Molecule Type, H1 2013 188
Assessment by Stage and Molecule Type, H1 2013 189

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *